Skip to main content
Figure 1 | BMC Musculoskeletal Disorders

Figure 1

From: High hopes for cannabinoid agonists in the treatment of rheumatic diseases

Figure 1

Cannabinoids have multiple actions in the synovium. The synovium is a richly vascularised and innervated tissue that becomes inflamed in both RA[12] and OA[13]. Fibroblast-like synovial cells (FLS) lie at the heart of synovial tissue; producing synovial fluid and mediating both pro- and anti-inflammatory properties of the synovium. A number of cytokines act on the FLS and induce release of further cytokines. The CB2 receptor is expressed more in the RA synovium than that of the OA joint. Production of CCL2, MMP-3 and IL-6 were all suppressed by the selective CB2 agonist JWH133 applied to in TNF-α stimulated FLS. Monocyte osteoclastogenesis was also suppressed. These factors are all important in arthritis. IL-6 mediates pain, MMP-3 mediates cartilage destruction and CCL-2 is a monocyte chemoattractant protein. Monocytes giving rise to osteoclasts (which re-absorb bone) and infiltrating macrophages that perpetuate inflammation. Action of cannabinoids will prove more complex however in complete joints, since CB2 receptors interact with TRPV1 and have been reported to increase afferent nerve firing[14], and chondrocytes express both CB1 and CB2 under some conditions[15].

Back to article page